---
$id: https://graph.org.ai/products/commodity/51111731
$type: Product
source: UNSPSC
code: "51111731"
title: "Bevacizumab"
class: "51111700"
classTitle: "Antineoplastic antibiotics"
family: "51110000"
familyTitle: "Antineoplastic agents"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Bevacizumab

**UNSPSC Code**: 51111731
**Class**: [Antineoplastic antibiotics](Antineoplastic antibiotics.mdx)
**Family**: [Antineoplastic agents](../Antineoplastic agents.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody anti-vegf with the molecular formula C6638H10160N1720O2108S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S9ZZM9Q9V, more generally known as bevacizumab. European Medicines Agency schedules bevacizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16402MIG. The term BEVACIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45. Most nations schedule Bevacizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BEVACIZUMAB remains the US FDA Preferred Term for this commodity. . Bevacizumab bears US NLM identifiers UMLS ID C0796392 and NCI Concept Code C2039.

